Im­munome buys desmoid tu­mor as­set; UK looks in­to Ther­mo Fish­er-Olink deal; Kyver­na's up­sized IPO

Plus, news about At­tralus, Sang­amo, Mithra, NeOnc, 4D Mol­e­c­u­lar Ther­a­peu­tics and Im­mix Bio­phar­ma:

Im­munome buys Ay­ala’s desmoid tu­mor as­set: The biotech will pay $20 mil­lion in cash and $30 mil­lion in stock to Ay­ala, with an­oth­er $37.5 mil­lion in mile­stones. The oral treat­ment can­di­date is a gam­ma sec­re­tase in­hibitor that’s cur­rent­ly in a Phase III tri­al. “We al­so plan to in­ves­ti­gate oth­er pop­u­la­tions of can­cer pa­tients that could ben­e­fit from treat­ment with AL102,” Im­munome CEO Clay Sie­gall, the for­mer chief ex­ec­u­tive at Seagen, said in a re­lease. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER